Monitor for additional insider purchases in the coming weeks; if buying continues, it could signal stronger conviction. Next catalyst is the annual meeting and any updates on guidance. The EPS miss due to one-time costs may be temporary, but guidance maintained provides some reassurance.
ANIK drugs
ANIK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $14.85entry
- T+1 · 7mo ago −2.02%α −1.65% · $14.55
- T+5 · 6mo ago −0.54%α −2.89% · $14.77
- T+20 · 6mo ago −1.48%α −6.74% · $14.63
- T+60 · 4mo ago +8.89%α +7.41% · $16.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 earnings release. Revenue of $29.6M beat consensus but GAAP EPS of -$0.37 missed estimates. The insider buying suggests confidence in the company's outlook, but the EPS miss tempers enthusiasm.
Key Financial Metrics
Key Facts
- CEO Stephen Griffin purchased 12,200 shares for ~$150K at $12.29 on April 30.
- Director John Henneman III purchased 5,000 shares for ~$73K at $14.66 on May 1.
- Q1 2026 revenue $29.6M (+13% YoY) beat consensus of $28.1M.
- Q1 2026 GAAP EPS -$0.37 missed consensus -$0.21, with $4.9M in severance costs.
- Total insider buying $223K represents ~0.11% of market cap ($198M).
Financial Impact
$223K in insider purchases (0.11% of market cap)
Risk Factors
- Q1 EPS miss of 76% versus consensus may weigh on sentiment despite revenue beat.
- Two director resignations announced with earnings could signal governance issues.
- Modest insider buying relative to market cap limits signal strength.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ANIK-1777898119851 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Viewing Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers